To switch or not to switch: Should the updated Intergroup exemestane Study alter our decision?

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 9-13

  Iddon, Julie ^a   Bundred, Nigel J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aromatase inhibitor; Breast cancer; Estrogen receptor; Exemestane; IES; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN; ANDROSTANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; ARTHRALGIA; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; EARLY CANCER; ENDOMETRIUM POLYP; FRACTURE; GYNECOLOGIC DISEASE; HAZARD RATIO; HUMAN; MORTALITY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; POSTMENOPAUSE; THROMBOEMBOLISM; TREATMENT DURATION; UTERUS DISEASE; BREAST TUMOR; FEMALE; NEOPLASM; REVIEW;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 38349030785     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.9     Document Type: Article

References (18)

1. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
2. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
3. Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 18, 859-867 (2007).
4. Coombes RC, Hall E, Gibson LJ et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
5. Jakesz R, Jonat W, Gnant M et al. Switching of post menopausal women with endocrine responsive early breast cancer to anastrozolc after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-461 (2005).
6. Jonat W, Gnant M, Boccardo et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 7, 991-996 (2006).
7. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen - treatment. (Intergroup exemestane study): a randomised controlled trial. Lancet 369, 559-570 (2007).
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
9. Smith IE, Dowsett M, Ebbs SR et al.; IMPACT Trialists' Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxilen, of both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23, 5108-5016 (2005).
10. Pancholi S, Martin L-A, Lykkesfeldt AE et al. Upregulation of erbD2/erbB3 and enhanced signal transduction via the phosphatidylinositol 3-kinase pathway in a tamoxifen resistant breast cancer cell line. Breast Cancer Res Treat. (2002) (Abstract 670).
11. Goss PE, Ingle JN, Martino S et al. A randormsed trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
12. Ellis MJ, Coop A, Singh B. Mauriac L et al. Letrozole is more effective ncoadjuvant therapy than ramoxifen for ERBb1 and/or ERBB2 positive, oestrogen receptor positiveprimary breast cancers. J. Clin. Oncol. 19, 3808-3816 (2001).
13. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combinod results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
14. Boccardo F, Rubagotti A, Purtioni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 23, 5138-5147 (2005).
15. Coleman RE, Banks LM, Girgis SI et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data. Lancet Oncol. 8, 119-127 (2007).
16. Punglia RS, Kuntz KM, Winer EP Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J. Clin. Oncol. 23, 5178-5187 (2005).
17. Piccart-Gebhart MJ. Improving outcomes in early breast cancer: aromatase inhibitors in the adjuvant setting. Am. J. Oncol. Rev. 4(Suppl. 9), 16-22 (2005).
18. +) breast cancer on tamoxifen. Breast Cancer Res. Treat. 94(Suppl. 1), S124 (2005) (Abstract 3001).